Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.7995
+0.0756 (10.44%)
At close: Mar 28, 2025, 4:00 PM
0.7710
-0.0285 (-3.56%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Ocugen Revenue
In the year 2024, Ocugen had annual revenue of $4.05M, down -32.82%. Ocugen had revenue of $764.00K in the quarter ending December 31, 2024, a decrease of -45.78%.
Revenue (ttm)
$4.05M
Revenue Growth
-32.82%
P/S Ratio
53.43
Revenue / Employee
$42,684
Employees
95
Market Cap
233.47M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOCGN News
- 10 days ago - Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - GlobeNewsWire
- 23 days ago - Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease - GlobeNewsWire
- 5 weeks ago - Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 7 weeks ago - Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - GlobeNewsWire
- 2 months ago - Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 - GlobeNewsWire